![Targeted action graph](/content/dam/global/hcpportal/en_NG/Images/Products/Avamys/17-july-2020/targeted_action_graph.jpg)
![Retention of glucocorticoids](/content/dam/global/hcpportal/en_NG/Images/Products/Avamys/17-july-2020/retention_of_glucocorticoids_graph.jpg)
In vitro data – clinical significance is unknown
Pharmacodynamic profile of Avamys
![Video resources VIDEO](/content/dam/global/hcpportal/en_NG/Images/Products/Avamys/17-july-2020/video_resources_image.jpg)
Watch the video to find out more.
*Vs fluticasone propionate, budesonide, mometasone furoate and ciclesonide.
AR: allergic rhinitis; FF: fluticasone furoate; INCS: intranasal corticosteroids.
References
- Villa E, Magnoni MS, Micheli D, Canonica GW. A review of the use of fluticasone furoate since its launch. Expert Opin Pharmacother 2011;12(13):2107–2117.
- Baumann D, Bachert C, Högger P. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clin Exp Allergy. 2009;39(10):1540–1550.
- Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8(1):54.
- Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L660–667.
Avamys is a registered trademark of the GlaxoSmithKline group of companies